Roivant Discovery has a differentiated pipeline of targets with high biological and disease validation that have historically been challenging to design therapeutics.
Heterobifunctionals
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
KRAS
ADAR
WRN
Undisclosed
Undisclosed
Undisclosed
Covalency
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
Undisclosed
Undisclosed
Undisclosed
Best-in-Class Small Molecules
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
KRAS
Undisclosed
Undisclosed
Undisclosed
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
KRAS
ADAR
WRN
Undisclosed
Undisclosed
Undisclosed
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
Undisclosed
Undisclosed
Undisclosed
Best-in-Class Small Molecules
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development
KRAS
Undisclosed
Undisclosed
Undisclosed
Target ID
Hit Finding
Hit-to-Lead
Lead Optimization
Preclinical Development